Home › NDC Lookup › Ingredients › Sodium Polystyrene Sulfonate › 42806-0013-94
Sodium Polystyrene Sulfonate 4.1 meq/g Powder, For Suspension, 15 g — NDC 42806-0013-94 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Sodium Polystyrene Sulfonate 4.1 meq/g Powder, For Suspension, 15 g — NDC 42806-013-94 (Billing 42806-0013-94)

by Epic Pharma, LLC · 15 g in 1 BOTTLE

This is a package of 15 g of Sodium Polystyrene Sulfonate 4.1 meq/g Powder, For Suspension from Epic Pharma, LLC, marketed since Apr 2014 and currently FDA-listed; retail pharmacies pay about $0.4741 per g (NADAC).

NDC 42806-0013-94
🏷️ FDA NDC (as labeled) 42806-013-94 billing pads the product segment with a zero
This package
Contains15 g Cost per g$0.4741 NADAC Per package$7.11 / 15 g Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.2872/unit · Part D plans $0.1789/unit — full pricing hub ↓
Product page 42806-0013-96 Also comes in: 453.6 g 42806-013-96
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 42806-013-94
Product NDC 42806-013
11-digit billing NDC 42806001394
NCPDP billing unit GM — per gram (weight)
RxCUI 2101899
UNII 1699G8679Z
UPC 0342806013946
Application # ANDA202333
SPL Set ID 61cc890b-eb3d-494c-ae45-629a27e721ce
Established class (EPC) Potassium Binder
Mechanism of action Potassium Ion Exchange Activity
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2014-04-14
Route ORAL
Dosage form POWDER, FOR SUSPENSION
Substance SODIUM POLYSTYRENE SULFONATE
TE code (Orange Book) AA · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 99450010002900
GPI class Sodium Polystyrene Sulfonate
GCN Seq No 001194
GCN 02890
HICL code 013209
Ingredient (HICL) Sodium Polystyrene Sulfonate
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C1
Therapeutic class — intermediate (HIC2) Drugs Affecting Electrolyte Balance
HIC3 code C1A
Therapeutic class — specific (HIC3) Electrolyte Depleters
AHFS code 40:18.18.00
AHFS class Potassium-Removing Agents
FDB label name SODIUM POLYSTYRENE SULF POWDER
FDB brand name Sodium Polystyrene Sulfonate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 001194
  • GCN: 02890
  • GPI-14 (Medi-Span): 99450010002900
  • HICL (First Databank): 013209
  • AHFS class code: 40:18.18.00
  • RxCUI (RxNorm): 2101899
Why two NDCs? The FDA registers this code as 42806-013-94 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 42806-0013-94. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name SODIUM POLYSTYRENE SULF POWDER Ingredient Sodium Polystyrene Sulfonate
📗 Our plain-language guide HelloPharmacist
  • Think of it like a sponge that travels through your gut. It swaps out sodium for potassium along the way, grabbing extra potassium and carrying it out of your body in your stool. Y...
  • What exactly is this medicine doing to my body?
  • That's one of the most important things to understand about this medicine — it's slow. It can take anywhere from several hours to a couple of days to meaningfully lower your potass...
  • No — and this is really important. This resin can grab on to other medications in your stomach and prevent them from being absorbed properly. You need to take all your other oral m...
📖 Read our full Sodium Polystyrene Sulfonate guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.474 $7.11 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.2872 $4.31 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.1789 $2.68 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.474 $0.311
▲ Up 48% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
42806-0013-94 You're viewing this 15 g in 1 BOTTLE $0.4741 / g $7.11 2022-09-15 — Active
42806-0013-96 42806-013-96 Main listing 453.6 g in 1 JAR $0.1552 / g $70.39 2014-04-14 — Active

Per g, this pack runs about 205% above the cheapest pack (453.6 g in 1 JAR (42806-, $0.1552 vs $0.4741 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 50% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 15 g — 15 g in 1 bottle.
How does this package differ from NDC 42806-0013-96?
Both are Sodium Polystyrene Sulfonate 4.1 meq/g Powder, For Suspension — the drug itself is identical. This page's package is the 15 g one, while NDC 42806-0013-96 is the 453.6 g package. Per-g NADAC also differs: $0.4741 here vs $0.1552 for the 453.6 g pack.
What NDC number is used to bill for this package of Sodium Polystyrene Sulfonate 4.1 meq/g Powder, For Suspension?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Sodium Polystyrene Sulfonate 1 g/g 46287-0012-16 CMP 454 g $0.092 AA Availability likely save 81%
Sodium Polystyrene Sulfonate 4.1 meq/g 24658-0760-16 PuraCap 453.6 g $0.155 AA Availability likely save 67%
Sodium Polystyrene Sulfonate 1 g/g 10702-0036-15 KVK-Tech, 15 g $0.474 AA Availability likely —
Sodium Polystyrene Sulfonate 4.1 meq/gthis 42806-0013-94 Epic 15 g $0.474 AA Availability likely —
Sodium Polystyrene Sulfonate 4.1 meq/g 11534-0166-15 SUNRISE 15 g $0.529 — FDA listed +12%
Sodium Polystyrene Sulfonate 4.1 meq/g 17856-0024-01 ATLANTIC 50 cups — AA FDA listed —
Sodium Polystyrene Sulfonate 4.1 meq/g 62135-0340-11 Chartwell 10 bottles — AA FDA listed —
Sodium Polystyrene Sulfonate 4.1 meq/g 63629-2390-01 Bryant 454 g — — FDA listed —
Sodium Polystyrene Sulfonate 4.1 meq/g 63629-8849-01 Bryant 15 g — — FDA listed —
Sodium Polystyrene Sulfonate 4.1 meq/g 63629-8850-01 Bryant 15 g — — FDA listed —
Sodium Polystyrene Sulfonate 4.1 meq/g 71335-2855-01 Bryant 15 g — — FDA listed —
Sodium Polystyrene Sulfonate 4.1 meq/g 72162-1230-02 Bryant 454 g — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2014
On the market since
Apr 2014
📍
2026
Currently FDA-listed
12 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

A current SPL was checked, but it does not contain a structured or narrative inactive-ingredient list for this product. This does not mean the product has no inactive ingredients.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerEpic Pharma, LLC
Application holderEPIC PHARMA LLC
FDA applicationANDA202333 (ANDA)
Labeler code42806
First marketedApr 2014
Product typeHuman Prescription Drug
Portfolio171 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 🧬 Mechanism of Action 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients 🧬 Pharmacokinetics 🧬 Pharmacodynamics 🧪 Nonclinical Toxicology 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 93 words ▾

1 INDICATIONS AND USAGE Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia. Limitation of Use: Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2)] . Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia (1) .

Limitation of Use: Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action (1) .

⏱️ Dosage and Administration ~2 min read ▾

2 DOSAGE AND ADMINISTRATION Oral : The average total daily adult dose of Sodium Polystyrene Sulfonate Powder, for Suspension is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily ( 2.1 ). Rectal : The average adult dose is 30 g to 50 g every six hours ( 2.1 ).

2.1General Information Administer Sodium Polystyrene Sulfonate Powder, for Suspension at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation [ see Warnings and Precautions (5.5) and Drug Interaction (7) ]

2.2Recommended Dosage The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia. Oral The average total daily adult dose of Sodium Polystyrene Sulfonate Powder, for Suspension is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily. Rectal The average adult dose is 30 g to 50 g every six hours.

2.3Preparation and Administration Prepare suspension fresh and use within 24 hours. Do not heat Sodium Polystyrene Sulfonate Powder, for Suspension as it could alter the exchange properties of the resin. One level teaspoon contains approximately 3.5 g of Sodium Polystyrene Sulfonate Powder, for Suspension and 15 mEq of sodium.

Oral Suspension Suspend each dose in a small quantity of water or syrup, approximately 3 to 4 mL of liquid per gram of resin. Administer with patient in an upright position [ see Warnings and Precautions (5.4) ] . Enema After an initial cleansing enema, insert a soft, large size (French 28) rubber tube into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and tape in place.

Administer as a warm (body temperature) emulsion in 100 mL of aqueous vehicle and flush with 50 to 100 ml of fluid. A somewhat thicker suspension may be used, but do not form a paste. Agitate the emulsion gently during administration.

The resin should be retained for as long as possible and follow by a cleansing enema with a nonsodium containing solution. Ensure an adequate volume of cleansing solution (up to 2 liters) is utilized.

💊 Dosage Forms and Strengths 49 words ▾

3 DOSAGE FORMS AND STRENGTHS Sodium Polystyrene Sulfonate Powder, for Suspension is a cream to light brown, finely ground powder and is available in 453.6 g jars and 15 g bottles. Sodium Polystyrene Sulfonate Powder, for Suspension is available as a cream to light brown, finely ground powder (3)

⛔ Contraindications 51 words ▾

4 CONTRAINDICATIONS Sodium Polystyrene Sulfonate Powder, for Suspension is contraindicated in patients with the following conditions: • Hypersensitivity to polystyrene sulfonate resins • Obstructive bowel disease • Neonates with reduced gut motility • Hypersensitivity to polystyrene sulfonate resins (4) • Obstructive bowel disease (4) • Neonates with reduced gut motility (4)

⚠️ Warnings and Cautions ~2 min read ▾

5 WARNINGS AND PRECAUTIONS • Intestinal Necrosis: cases of intestinal necrosis and other serious gastrointestinal events have been reported ( 5.1 ). • Electrolyte Disturbances: Severe hypokalemia can occur. ( 5.2 ). • Fluid overload in patient sensitive to high sodium intake: Monitor patients who are sensitive to sodium intake for signs of fluid overload. ( 5.3 ). • Risk of aspiration: Acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles has been reported.

( 5.4 ).

5.1Intestinal Necrosis Cases of intestinal necrosis, some fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with Sodium Polystyrene Sulfonate Powder, for Suspension use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure.

Concomitant administration of sorbitol is not recommended. • Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery. • Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction). Discontinue use in patients who develop constipation.

5.2Electrolyte Disturbances Monitor serum potassium during therapy because severe hypokalemia may occur. Sodium Polystyrene Sulfonate Powder, for Suspension is not totally selective for potassium, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Monitor calcium and magnesium in patients receiving Sodium Polystyrene Sulfonate Powder, for Suspension.

5.3Fluid Overload in Patients Sensitive to High Sodium Intake Each 15 g dose of Sodium Polystyrene Sulfonate Powder, for Suspension contains 1500 mg (60 mEq) of sodium. Monitor patients who are sensitive to sodium intake (heart failure, hypertension, edema) for signs of fluid overload. Adjustment of other sources of sodium may be required.

5.4Risk of Aspiration Cases of acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles have been reported. Patients with impaired gag reflex, altered level of consciousness, or patients prone to regurgitation may be at increased risk. Administer Sodium Polystyrene Sulfonate Powder, for Suspension with the patient in an upright position.

5.5Binding to Other Orally Administered Medications Sodium Polystyrene Sulfonate Powder, for Suspension may bind orally administered medications, which could decrease their gastrointestinal absorption and lead to reduced efficacy. Administer other oral medications at least 3 hours before or 3 hours after Sodium Polystyrene Sulfonate Powder, for Suspension. Patients with gastroparesis may require a 6 hour separation. [ see Dosage and Administration (2.1) and Drug Interactions (7) ] .

🤒 Adverse Reactions 150 words ▾

6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in the labeling: • Intestinal Necrosis [ see Warnings and Precautions (5.1) ] • Electrolyte Disturbances [see Warnings and Precautions (5.2, 5.3) ] • Aspiration [ see Warnings and Precautions (5.4) ] The following adverse reactions have been identified during post-approval use of Sodium Polystyrene Sulfonate Powder, for Suspension. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.

Gastrointestinal: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, ulcerations, vomiting, gastric irritation, intestinal obstruction (due to concentration of aluminium hydroxide) Metabolic: systemic alkalosis Adverse reactions reported include: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, vomiting (6) . To report SUSPECTED ADVERSE REACTIONS, contact Epic Pharma, LLC 1-888-374-2791 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🔄 Drug Interactions ~1 min read ▾

7 DRUG INTERACTIONS • Take other orally administered drugs at least 3 hours before or 3 hours after Sodium Polystyrene Sulfonate Powder, for Suspension ( 7.1 ). • Cation-Donating Antacids: may reduce the resin’s potassium exchange capability and increase risk of systemic alkalosis ( 7.2 ). • Sorbitol: Concomitant use may contribute to the risk of intestinal necrosis and is not recommended ( 7.3 ).

7.1General Interactions No formal drug interaction studies have been conducted in humans. Sodium Polystyrene Sulfonate Powder, for Suspension has the potential to bind other drugs. In in vitro binding studies, Sodium Polystyrene Sulfonate Powder, for Suspension was shown to significantly bind the oral medications (n=6) that were tested.

Decreased absorption of lithium and thyroxine have also been reported with co-administration of Sodium Polystyrene Sulfonate Powder, for Suspension. Binding of Sodium Polystyrene Sulfonate Powder, for Suspension to other oral medications could cause decreased gastrointestinal absorption and loss of efficacy when taken close to the time Sodium Polystyrene Sulfonate Powder, for Suspension is administered. Administer Sodium Polystyrene Sulfonate Powder, for Suspension at least 3 hours before or 3 hours after other oral medications.

Patients with gastroparesis may require a 6 hour separation. Monitor for clinical response and/or blood levels where possible.

7.2Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis

7.3Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and Precautions (5.1) ] and concomitant use is not recommended.

👥 Use in Specific Populations 176 words ▾

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Risk Summary Sodium Polystyrene Sulfonate Powder, for Suspension is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk.

8.2Labor and Delivery Risk Summary Sodium Polystyrene Sulfonate Powder, for Suspension is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant.

8.4Pediatric Use Studies of safety and efficacy have not been conducted in pediatric patients. In pediatric patients, as in adults, Sodium Polystyrene Sulfonate Powder, for Suspension is expected to bind potassium at the practical exchange ratio of 1mEq potassium per 1 gram of resin. In neonates, Sodium Polystyrene Sulfonate Powder, for Suspension should not be given by the oral route.

In both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. Premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with Sodium Polystyrene Sulfonate Powder, for Suspension use [ see Warnings and Precautions (5.4) ] .

🤰 Pregnancy 30 words ▾

8.1Pregnancy Risk Summary Sodium Polystyrene Sulfonate Powder, for Suspension is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk.

🧒 Pediatric Use 110 words ▾

8.4Pediatric Use Studies of safety and efficacy have not been conducted in pediatric patients. In pediatric patients, as in adults, Sodium Polystyrene Sulfonate Powder, for Suspension is expected to bind potassium at the practical exchange ratio of 1mEq potassium per 1 gram of resin. In neonates, Sodium Polystyrene Sulfonate Powder, for Suspension should not be given by the oral route.

In both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. Premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with Sodium Polystyrene Sulfonate Powder, for Suspension use [ see Warnings and Precautions (5.4) ] .

🆘 Overdosage 42 words ▾

10 OVERDOSAGE Overdosage may result in electrolyte disturbances including hypokalemia, hypocalcemia, and hypomagnesemia. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas.

🧬 Clinical Pharmacology ~1 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Sodium Polystyrene Sulfonate Powder, for Suspension is a non-absorbed, cation exchange polymer that contains a sodium counterion. Sodium Polystyrene Sulfonate Powder, for Suspension increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels.

The practical exchange ratio is 1 mEq K per 1 gram of resin. As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. This action occurs primarily in the large intestine, which excretes potassium ions to a greater degree than does the small intestine.

The efficiency of this process is limited and unpredictably variable.

12.2Pharmacodynamics The effective lowering of serum potassium with Sodium Polystyrene Sulfonate Powder, for Suspension may take hours to days.

12.3Pharmacokinetics The in vivo efficiency of sodium-potassium exchange resins is approximately 33 percent; hence, about one third of the resin's actual sodium content is delivered to the body. Sodium Polystyrene Sulfonate Powder, for Suspension is not absorbed systemically. Drug Interactions In vitro binding studies showed that Sodium Polystyrene Sulfonate Powder, for Suspension bound significantly to the following tested drugs - warfarin, metoprolol, phenytoin, furosemide, amlodipine and amoxicillin.

🧬 Mechanism of Action 136 words ▾

12.1Mechanism of Action Sodium Polystyrene Sulfonate Powder, for Suspension is a non-absorbed, cation exchange polymer that contains a sodium counterion. Sodium Polystyrene Sulfonate Powder, for Suspension increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels.

The practical exchange ratio is 1 mEq K per 1 gram of resin. As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. This action occurs primarily in the large intestine, which excretes potassium ions to a greater degree than does the small intestine.

The efficiency of this process is limited and unpredictably variable.

📦 How Supplied / Storage and Handling 52 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING Sodium Polystyrene Sulfonate Powder, for Suspension is available as a cream to light brown, finely ground powder in jars of 1 pound (453.6 g). NDC 42806-013-96, and in bottles of 15 g, NDC 42806-013-94. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

📋 Description 115 words ▾

11 DESCRIPTION Sodium Polystyrene Sulfonate Powder, for Suspension is a benzene, diethenyl-polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula: The drug is a cream to light brown finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an in vitro exchange capacity of approximately 3.1 mEq ( in vivo approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug.

It can be administered orally or rectally as an enema. One gram of Sodium Polystyrene Sulfonate Powder, for Suspension contains 4.1 mEq of sodium. L:\Labeling Department\ANDA\Sodium Polystyrene Sulfonate_SZ- Done\Epic\Package Insert\2017.10 RLD update\Platimun\Docs for Submission\SBS\Structure

💬 Information for Patients 62 words ▾

17 PATIENT COUNSELING INFORMATION Drug Interactions Advise patients who are taking other oral medication to separate the dosing of Sodium Polystyrene Sulfonate Powder, for Suspension by at least 3 hours (before or after) [ see Dosage and Administration (2.1), Warnings and Precautions (5.5), and Drug Interactions (7.1) ] Rx Only Manufactured by: Epic Pharma, LLC Laurelton, NY 11413 Rev. 07-2023-00 MF013REV07/23 OE1063

🧬 Pharmacokinetics 68 words ▾

12.3Pharmacokinetics The in vivo efficiency of sodium-potassium exchange resins is approximately 33 percent; hence, about one third of the resin's actual sodium content is delivered to the body. Sodium Polystyrene Sulfonate Powder, for Suspension is not absorbed systemically. Drug Interactions In vitro binding studies showed that Sodium Polystyrene Sulfonate Powder, for Suspension bound significantly to the following tested drugs - warfarin, metoprolol, phenytoin, furosemide, amlodipine and amoxicillin.

🧬 Pharmacodynamics 20 words ▾

12.2Pharmacodynamics The effective lowering of serum potassium with Sodium Polystyrene Sulfonate Powder, for Suspension may take hours to days.

🧪 Nonclinical Toxicology 14 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 11 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed.

📄 Package Label / Principal Display Panel 16 words ▾

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 453.6 g sodium-453.6g.jpg

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 15 g sodium-15g.jpg

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
138
Units reimbursed last 4 qtrs
14.6K
Gross reimbursed last 4 qtrs
$4.2K
Avg / prescription
$30.41
Avg / unit
$0.2872
Latest quarter Q1 2026
127Rx
Medicaid pays / g
$0.2872
gross reimbursed
vs
NADAC / g
$0.4741
acquisition cost
=
Spread
−$0.1869
-39% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
52% FFS 48% MCO
Fee-for-service · 72 Rx Managed care · 66 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 2,850 units · 14.6 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: 2,535 units · 27.3 per 100k residents NJ Massachusetts: no data reported MA California: 5,760 units · 14.8 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: 465 units · 15.8 per 100k residents KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: 1,465 units · 6.5 per 100k residents FL
Units reimbursed · per 100k residents
6.527.3
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Jersey 27.3 /100k
2 Kansas 15.8 /100k
3 California 14.8 /100k
4 New York 14.6 /100k
5 Florida 6.5 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
15 g this page42806-0013-94 138 Rx · $4,197
453.6 g42806-0013-96 137 Rx · $17,179
Drug total (last 4 qtrs): 275 Rx · 82,340 units · $21,376 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Sodium Polystyrene Sulfonate — the program that covers self-administered drugs. 6 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Sodium Polystyrene Sulfonate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$858.1K
Claims incl. refills
13.3K
Beneficiaries
10.4K
Spend / beneficiary
$82.68
Spend / claim
$64.41
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 42806-0012-01 · Epic 42806-0014-01 · Epic →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.